Immuron takes another step towards addressing US$10 billion CDI market
Shares in biopharmaceutical group Immuron (ASX: IMC) traded as high as 22 cents on Monday, representing an increase of more than 7%, after the company announced that it had successfully initiated the first-in-human, IMM-529 clinical study for the treatment of Clostridium Difficile Infection (CDI).
Of course it should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
CDI is the causative organism of antibiotic-associated colitis. The organism is capable of elaborating exotoxins that bind to receptors on intestinal epithelial cells, leading to inflammation and diarrhoea and, in severe cases, death. This condition has become a major medical concern causing an estimated annual economic burden of more than US$10 billion globally.
Immuron is pursuing the biopharmaceutical research and development of an effective and safe treatment of CDI which according to the Centre for Disease Control and Prevention (CDC), infects more than 450,000 patients causing over 29,000 deaths, per year in the United States alone.
The IMM-529 drug product has been shown in pre-clinical tests to be an effective treatment. Success in this trial will provide a firm foundation to the Board and Management that the company’s IMM-529 drug product has significant potential for continued clinical development.
Having received appropriate approvals to perform the clinical study, IMC has now implemented the opening of the site to enrol its first 60 patients by mid-September 2017.
This Phase 1/2 randomised, double-blind, placebo-control clinical study is designed to evaluate the safety and preliminary efficacy of IMC’s IMM-529 drug product for the treatment of CDI.
Commenting on this development, Dr. Dan Peres, IMC’s Chief Medical Officer said, “Immuron’s IMM-529 compound is a unique combination of polyclonal antibodies, targeting all main virulence factors of CDI, and we anticipate it will exhibit the same level of safety as previously demonstrated with our other compounds while its ‘one-of-a-kind’ mechanism of action should relieve the diseased gut of the infectious and toxic burden to allow the microbiome to recuperate and reinstate homeostasis”.
Peres believes the company is positioned to address a significant addressable market given that there is a true void in relation to the effective treatment of CDI.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.